Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy

Driessen, J.T.; Heijden, Elisabeth A. Wammes-van der; Verschuure, P.; Fasen, K.C.F.M.; Teunissen, Maria W A; Majoie, H.J.M.

doi:10.1016/j.ebr.2022.100574

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most common adverse drug reactions were dizziness and somnolescence. Most studies have reported dizziness as the most common adverse drug reaction 16,17 .…”

Section: Fig 1: Study Flow Chartmentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

Background: Epilepsy is a common and chronic neurological disorder. The prevalence of drug-resistant epilepsy (DRE) is reported as 25-30% among epileptic patients. So, there is a need of drugs for resistant epilepsy. Objective: To assess the effectiveness and tolerability of Lacosamide (LCM) as an add-on therapy in patients with Drug-Resistant Epilepsy in our patient population. Methods and Material: A total of 43 patients with Drug Resistant Epilepsy were screened, and 32 were included in the study based on inclusion and exclusion criteria and Lacosamide was added as an add-on therapy, and the patients were prospectively followed up for a minimum 3 months. Out of 32 patients, 25 had focal and the remaining 7 were having generalized epilepsy. The Lacosamide dosage used was between 4 -12mg/kg/day. Seizure frequency, adverse effects, and tolerability were noted in the study participants. Results: Two patients lost follow-up. Hence 30 patients were taken for intension to treat analysis. Out of 30 patients with DRE, 11(36.6%), 25(83.3%) had seizure reduction of more than 90%, 50% respectively. None of the patients developed significant adverse effects so as to warrant discontinuation of the drug. Conclusion: Lacosamide was found to have been better tolerated and was effective in reducing seizure frequency of more than 50% in patients with Drug-Resistant Epilepsy of both focal and generalized epilepsy in our patient population. INTRODUCTION:Epilepsy is one of the most common and chronic neurological disorders. The prevalence of epilepsy in India is estimated to be approximately 8-10 per 1000 1 . It is estimated that 20 to 30% of epilepsy patients are refractory to medical treatment 2 . Hence, the development of new therapeutic options and various drug combinations are strongly warranted.

show abstract

“…Most common adverse drug reactions were dizziness and somnolescence. Most studies have reported dizziness as the most common adverse drug reaction 16,17 .…”

Section: Fig 1: Study Flow Chartmentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

show abstract

“…In 2022, Tayla et al (2022) conducted a retrospective cohort study to assess LCM as an add-on therapy for children with refractory epilepsy and found there was a reduction of >50% in the frequency of seizures in 73.1% of the children after 3 months treatment. Driessen et al, 2022 retrospectively evaluated the efficacy and tolerability of LCM in children with drug resistant epilepsy and concluded that LCM is an effective ASM with acceptable side-effects in children with drug-resistant epilepsy.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of Lacosamide therapy for children with focal epilepsy: a real world study

et al. 2023

View full text Add to dashboard Cite

Objectives: To compare the effectiveness and safety of the new antiepileptic drug, lacosamide (LCM) with Levetiracetam, for the treatment of focal epilepsy in children.Methods: This study was a cohort study. Children with focal epilepsy who received LCM or Levetiracetam treatment in West China Second Hospital of Sichuan University were recruited and followed up for 12 months. Changes in the frequency of epilepsy, 50% and 75% responder rates, and seizure freedom rates from baseline to the maintenance period and adherence score were assessed. In addition, adverse events (AEs) were recorded.Results: 92 patients completed the study, and were divided into two groups: LCM (n = 46) and Levetiracetam (n = 46). Participants were aged from 2 to 16.3 years, with a mean epilepsy duration of 2.57 years. The average maintenance dose of LCM was 5.03 ± 1.91 mg/kg/d after the titration period. There was no significant difference between the two groups in terms of the mean seizure frequency during subsequent visits at 1, 3,6, 9, 12 months. There was significant difference between the two groups in terms of the 50% responder rate at 6 months. No serious AEs were reported in both groups. The vast majority of patients had good adherence (adherence score = 4) in the LCM group.Conclusion: LCM is effective as adjunctive therapy in children with epilepsy and has good safety, tolerability and adherence. Large sample size studies with long-term follow-up are needed in the future to comprehensively evaluate the use of LCM in children.Clinical Trial Registration: [https://www.chictr.org.cn/showproj.html?proj=41041], identifier [ChiCTR1900024507].

show abstract

Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system

Liu

et al. 2023

Seizure: European Journal of Epilepsy

View full text Add to dashboard Cite

Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy

Cited by 6 publications

References 19 publications

Untitled

Untitled

Effectiveness and safety of Lacosamide therapy for children with focal epilepsy: a real world study

Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system

Contact Info

Product

Resources

About